The US Court of Appeals for the Fourth Circuit recently reinstated a significant lawsuit from West Virginia, spotlighting the intricate legal battles over opioid distribution. This decision is set to impact the ongoing debate about corporate responsibility in the opioid crisis, as it vacated a 2022 district court ruling in City of Huntington, West Virginia v. AmerisourceBergen Drug Corporation et al. The ruling initially found drug distributors AmerisourceBergen, Cardinal Health, and McKesson Corporation not liable for claims made against them. These companies, controlling over 90% of the US opioid distribution market, were accused of contributing to the opioid epidemic by neglecting their duties.
A cornerstone of the appeals court’s decision was the interpretation of West Virginia common law, which permits public nuisance claims for the conditions resulting from opioid over-distribution. The court found that the district court erred in excluding product-based harms from public nuisance claims. The distributors’ responsibilities under the Controlled Substances Act were misinterpreted, with evidence showing that suspicious orders were repeatedly fulfilled without appropriate reporting.
This ruling remands the case to the district court under updated legal standards, placing potential exposure to a substantial $2.5 billion abatement plan proposed by the plaintiffs. In issuing guidance on possible remedies, the appeals court emphasized that equitable solutions could involve monetary awards to support treatment facilities and community recovery programs, referencing the case of United States v. Price.
This legal development adds to a series of recent actions against entities linked to the opioid crisis. Notably, New York State reached a $7.5 billion settlement with Purdue Pharmaceuticals earlier this year, and the US Justice Department has pursued a lawsuit against Walgreens for allegedly fulfilling millions of prescriptions without legitimate medical purposes, as detailed in a Reuters report.
The re-emergence of this lawsuit highlights the judiciary’s evolving stance on corporate accountability amid an ongoing public health crisis, offering a potential pathway to meaningful relief for affected communities through the courts.